Novel tyrosine kinase inhibitors in chronic myelogenous leukemia

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW: The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia. RECENT FINDINGS: Imatinib therapy has significantly improved prognosis of chronic myeloid leukemia. A minority of patients with chronic-phase disease (4% annually) and considerably more in advanced stages develop resistance. This is attributed, in 40-50% of cases, to the development of BCR-ABL (breakpoint cluster region/Abelson oncogene) tyrosine kinase domain mutations that impair imatinib binding. This has led to the development of more potent novel tyrosine kinase inhibitors that can overcome both BCR-ABL-dependent and BCR-ABL-independent mechanisms of resistance. Preliminary results of phase I and II trials with dasatinib and nilotinib have provided promising data that may reduce disease progression and potentially prevent acquired resistance to the tyrosine kinase inhibitors. SUMMARY: Novel tyrosine kinase inhibitors with more potent and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinases are promising and may further improve prognosis in chronic myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)578-583
Number of pages6
JournalCurrent Opinion in Oncology
Volume18
Issue number6
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Oncogenes
src-Family Kinases
Disease Progression
Chronic Disease
Mutation
Imatinib Mesylate
Therapeutics

Keywords

  • Chronic myeloid leukemia
  • Imatinib
  • Mutations
  • Novel tyrosine kinase inhibitors
  • Resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. / Jabbour, Elias; Cortes, Jorge; Kantarjian, Hagop.

In: Current Opinion in Oncology, Vol. 18, No. 6, 01.11.2006, p. 578-583.

Research output: Contribution to journalReview article

Jabbour, Elias ; Cortes, Jorge ; Kantarjian, Hagop. / Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. In: Current Opinion in Oncology. 2006 ; Vol. 18, No. 6. pp. 578-583.
@article{2b6dc72aa9de47a985f3c269bfb3b7e3,
title = "Novel tyrosine kinase inhibitors in chronic myelogenous leukemia",
abstract = "PURPOSE OF REVIEW: The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia. RECENT FINDINGS: Imatinib therapy has significantly improved prognosis of chronic myeloid leukemia. A minority of patients with chronic-phase disease (4{\%} annually) and considerably more in advanced stages develop resistance. This is attributed, in 40-50{\%} of cases, to the development of BCR-ABL (breakpoint cluster region/Abelson oncogene) tyrosine kinase domain mutations that impair imatinib binding. This has led to the development of more potent novel tyrosine kinase inhibitors that can overcome both BCR-ABL-dependent and BCR-ABL-independent mechanisms of resistance. Preliminary results of phase I and II trials with dasatinib and nilotinib have provided promising data that may reduce disease progression and potentially prevent acquired resistance to the tyrosine kinase inhibitors. SUMMARY: Novel tyrosine kinase inhibitors with more potent and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinases are promising and may further improve prognosis in chronic myeloid leukemia.",
keywords = "Chronic myeloid leukemia, Imatinib, Mutations, Novel tyrosine kinase inhibitors, Resistance",
author = "Elias Jabbour and Jorge Cortes and Hagop Kantarjian",
year = "2006",
month = "11",
day = "1",
doi = "10.1097/01.cco.0000245314.97638.d3",
language = "English (US)",
volume = "18",
pages = "578--583",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Novel tyrosine kinase inhibitors in chronic myelogenous leukemia

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2006/11/1

Y1 - 2006/11/1

N2 - PURPOSE OF REVIEW: The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia. RECENT FINDINGS: Imatinib therapy has significantly improved prognosis of chronic myeloid leukemia. A minority of patients with chronic-phase disease (4% annually) and considerably more in advanced stages develop resistance. This is attributed, in 40-50% of cases, to the development of BCR-ABL (breakpoint cluster region/Abelson oncogene) tyrosine kinase domain mutations that impair imatinib binding. This has led to the development of more potent novel tyrosine kinase inhibitors that can overcome both BCR-ABL-dependent and BCR-ABL-independent mechanisms of resistance. Preliminary results of phase I and II trials with dasatinib and nilotinib have provided promising data that may reduce disease progression and potentially prevent acquired resistance to the tyrosine kinase inhibitors. SUMMARY: Novel tyrosine kinase inhibitors with more potent and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinases are promising and may further improve prognosis in chronic myeloid leukemia.

AB - PURPOSE OF REVIEW: The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia. RECENT FINDINGS: Imatinib therapy has significantly improved prognosis of chronic myeloid leukemia. A minority of patients with chronic-phase disease (4% annually) and considerably more in advanced stages develop resistance. This is attributed, in 40-50% of cases, to the development of BCR-ABL (breakpoint cluster region/Abelson oncogene) tyrosine kinase domain mutations that impair imatinib binding. This has led to the development of more potent novel tyrosine kinase inhibitors that can overcome both BCR-ABL-dependent and BCR-ABL-independent mechanisms of resistance. Preliminary results of phase I and II trials with dasatinib and nilotinib have provided promising data that may reduce disease progression and potentially prevent acquired resistance to the tyrosine kinase inhibitors. SUMMARY: Novel tyrosine kinase inhibitors with more potent and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinases are promising and may further improve prognosis in chronic myeloid leukemia.

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Mutations

KW - Novel tyrosine kinase inhibitors

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=33748885930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748885930&partnerID=8YFLogxK

U2 - 10.1097/01.cco.0000245314.97638.d3

DO - 10.1097/01.cco.0000245314.97638.d3

M3 - Review article

C2 - 16988578

AN - SCOPUS:33748885930

VL - 18

SP - 578

EP - 583

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -